, Tracking Stock Market Picks
Enter Symbol:

up 943.82 %


Posted on: Wednesday,  Jul 11, 2007  9:25 AM ET by Lehman Brothers

Lehman Brothers rated Buy JAZZ PHARMA INC (NASDAQ: JAZZ) on 07/11/2007, when the stock price was $16.36. Since
then, JAZZ PHARMA INC has gained 943.83% as of 11/25/2015's recent price of $170.77.
If you would have followed this Lehman Brothers's recommendation on JAZZ, you would have gained 943.82% of your investment in 3059 days.

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products to meet unmet medical needs in neurology and psychiatry. The marketed products and late-stage product candidate of the Company include Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) extended-release capsules and JZP-6 (sodium oxybate). The other product candidates in clinical development are JZP-8 (intranasal clonazepam), being developed for the treatment of recurrent acute repetitive seizures in epilepsy patients who continue to have seizures while on stable anti-epileptic regimens, JZP-4 (sodium and calcium channel antagonist), being developed for the treatment of epilepsy and bipolar disorder, and JZP-7 (ropinirole gel), being developed for the treatment of restless legs syndrome.

Lehman Brothers Holdings Inc. has filed for bankruptcy protection in the U.S.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/11/2007 9:25 AM Buy
16.36 27.00
as of 8/27/2015
1 Week down  -6.06 %
1 Month down  -6.58 %
3 Months down  -2.69 %
1 YTD up  34.93 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy